Tempus AI's diagnostics and data businesses grew Q2 2026 revenue 19.4% year over year, with FDA approvals, expanded tests and pricing aimed…
SA Robert J. Lake Aug 20 3 clicks Norwegian Cruise Line’s $15 billion debt and 2026-27 capex delay deleveraging, despite fuel-efficient new ships and stronger projected 2028…
S The Oak Bloke Aug 19 14 clicks
Airbnb shares have risen about 50% since October 2025, prompting a revised 2026 model and return assumptions at the current price.
S MBI Deep Dives Aug 19 5 clicks
AppLovin’s AXON 2.0 self-serve rollout, e-commerce onboarding and Connected TV expansion aim to revive growth after Q2 2026 revenue and…
SA KL Research Aug 19 2 clicks IREN awarded each co-CEO roughly 9 million RSUs, about 2.5% of shares and $400 million, in exchange for no further equity grants until…
S Yet Another Value Blog Aug 18 13 clicks
Nubank's 140 million customers, 20% efficiency ratio and 30% ROE frame whether its high-teens P/E reflects a scalable fintech or a maturing…
YT Yet Another Value Podcast Aug 17 10 clicks
DoorDash’s integrated autonomous-delivery strategy contrasts with Uber’s 2026 divestment of Serve Robotics, its former delivery-robot…
S MBI Deep Dives Aug 17 5 clicks
Hyperscalers’ off-balance-sheet lease and purchase obligations rose from roughly $1 trillion to $1.5 trillion, turning the AI buildout into…
YT The Monetary Matters Network Aug 16 11 clicks
HubSpot trades near its 2020 share price despite quadrupled revenue and $750 million in free cash flow, with Breeze AI upside weighed…
S The Oak Bloke Aug 16 10 clicks
Steve Eisman argues the AI boom hinges on Anthropic and OpenAI’s importance to hyperscalers, while weighing software, CoreWeave and Cisco…
YT Steve Eisman Aug 14 11 clicks
PRYMY · short Prysmian (PRYMY) is presented as a short position.
BL Value Investors Club May 8 1 click
ICBC’s chairman describes embedding Chinese Communist Party leadership, anti-corruption campaigns and Xi Jinping Thought into governance at…
S John Hempton's Newsletter Nov 16 1 click
Justice Department remedies could bar Google from using location data it cannot share, weakening targeted ads and traffic routing despite…
S John Hempton's Newsletter Oct 9 5 clicks
Alnylam’s 2022 50% phase-three gain faces FDA advisory-panel scrutiny over its amyloidosis drug’s label extension.
S John Hempton's Newsletter Sep 12 1 click